Advances in Prostate Cancer Chemoprevention: A Translational Perspective

REFERENCES

• Jemal , A , Bray , F and Ferlay , J . 2011 . Global Cancer Statistics . Ca Cancer J Clin , 61 : 69 – 90 .
   PubMed Web of Science ®Google Scholar
• Bostwick , D G , Liu , L , Brawer , M K and Qian , J . 2004 . High-grade prostatic intraepithelial neoplasia . Reviews in Urology , 6 : 171 – 179 .
   PubMedGoogle Scholar
• Bostwick , D G and Cheng , L . 2012 . Precursors of prostate cancer . Histopathology , 60 : 4 – 27 .
   PubMed Web of Science ®Google Scholar
• Schaid , D J . 2004 . The complex genetic epidemiology of prostate cancer . Human Mol Genetics , 13 : R103 – R121 .
   PubMed Web of Science ®Google Scholar
• Tomlins , S A , Rhodes , D R , Perner , S , Dhanasekaran , S M Mehra , R . 2005 . Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer . Science , 310 : 644 – 648 .
   PubMed Web of Science ®Google Scholar
• Thompson , I M , Goodman , P J , Tangen , C M , Lucia , M S Miller , G J . 2003 . The influence of finasteride on the development of prostate cancer . N Engl J Med , 349 : 215 – 224 .
   PubMed Web of Science ®Google Scholar
• Musquera , M , Fleshner , N E , Finelli , A and Zlotta , A R . 2008 . The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride . Expet Rev Anticancer Ther , 8 : 1073 – 1079 .
   PubMed Web of Science ®Google Scholar
• Trottier , G , Lawrentschuk , N and Fleshner , N E . 2010 . Prevention strategies in prostate cancer . Curr Oncol , 17 : S4 – S10 .
   PubMed Web of Science ®Google Scholar
• Kaplan , S A , Roehrborn , C G , Meehan , A G , Liu , K S and Carides , A D . 2009 . PCPT: evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer . Urology , 73 : 935 – 939 .
   PubMed Web of Science ®Google Scholar
• Fleshner , N E , Lucia , M S , Egerdie , B , Aaron , L Eure , G . 2012 . Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial . Lancet , 379 : 1103 – 1111 .
   PubMed Web of Science ®Google Scholar
• Zhigang , Z and Wenlu , S . 2008 . Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia . Int J Cancer , 122 : 864 – 870 .
   PubMed Web of Science ®Google Scholar
• Finelli , A , Trottier , G , Lawrentschuk , N , Sowerby , R Zlotta , A R . 2011 . Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer . Eur Urol , 59 : 509 – 14 .
   PubMed Web of Science ®Google Scholar
• de Bono , J S , Logothetis , C J , Molina , A , Fizazi , K North , S . 2011 . Abiraterone and increased survival in metastatic prostate cancer . N Engl J Med , 364 : 1995 – 2005 .
   PubMed Web of Science ®Google Scholar
• Parkin , D M , Weelan , S L , Ferlay , W J , Teppo , L and Thomas , D B . 2002 . Cancer incidence in five continents . IARC Scientific Publications , 8 : 633 – 635 .
   Google Scholar
• Shu , Y Z . 1998 . Recent natural products based drug development: a pharmaceutical industry perspective . J Nat Prod , 61 : 1053 – 1071 .
   PubMed Web of Science ®Google Scholar
• Singh , R P , Sharma , G , Dhanalakshmi , S and Agarwal , C . 2003 . Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis . Cancer Epidemiol Biomarkers Prev , 12 : 933 – 939 .
   PubMed Web of Science ®Google Scholar
• Zi , X and Agarwal , R . 1999 . Silibinin decreases prostate-specific antigen with cell growth inhibition via G 1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention . Proc Natl Acad Sci , 96 : 7490 – 7495 .
   PubMed Web of Science ®Google Scholar
• Singh , R P , Raina , K , Deep , G , Chan , D and Agarwal , R . 2009 . Silibinin suppresses growth of human prostate carcinoma pc-3 orthotopic xenograft via activation of erk1/2 and inhibition of stat signaling . Clin Cancer Res , 15 : 613 – 621 .
   PubMed Web of Science ®Google Scholar
• Agarwal , C , Tyagi , A , Kaur , M and Agarwal , R . 2007 . Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells . Carcinogenesis , 28 : 1463 – 1470 .
   PubMed Web of Science ®Google Scholar
• Singh , R P and Agarwal , R . 2006 . Mechanisms of action of novel agents for prostate cancer chemoprevention . Endocrine-Related Cancer , 13 : 751 – 778 .
   PubMed Web of Science ®Google Scholar
• Roy , S , Kaur , M , Agarwal , C , Tecklenburg , M Sclafani , R A . 2007 . p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells . Mol Cancer Ther , 10 : 2696 – 2707 .
   Web of Science ®Google Scholar
• Raina , K , Blouin , M J , Singh , R P , Majeed , N Deep , G . 2007 . Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model . Cancer Res , 67 : 11083 – 11091 .
   PubMed Web of Science ®Google Scholar
• Singh , R P , Deep , G , Blouin , M J , Pollak , M N and Agarwal , R . 2007 . Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft . Carcinogenesis , 28 : 2567 – 2574 .
   PubMed Web of Science ®Google Scholar
• Singh , R P , Dhanalakshmi , S , Tyagi , A K , Chan , D C Agarwal , C . 2002 . Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels . Cancer Res , 62 : 3063 – 3069 .
   PubMed Web of Science ®Google Scholar
• Singh , R P , Raina , K , Sharma , G and Agarwal , R . 2008 . Preclinical silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate mode . Clin Cancer Res , 14 : 7773 – 7780 .
   PubMed Web of Science ®Google Scholar
• Flaig , T W , Gustafson , D L , Su , L J , Zirrolli , J A Crighton , F . 2007 . A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients . Invest New Drug , 25 : 139 – 146 .
   PubMed Web of Science ®Google Scholar
• Flaig , T W , Glodé , M , Gustafson , D , van Bokhoven , A Tao , Y . 2010 . A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer . Prostate , 70 : 848 – 855 .
   PubMed Web of Science ®Google Scholar
• Messina , M and Barnes , S . 1991 . The role of soy products in reducing risk of cancer . J. Natl Cancer Inst , 83 : 541 – 546 .
   PubMed Web of Science ®Google Scholar
• Li , Y , Wang , Z , Kong , D , Li , R Sarkar , S H . 2008 . Regulation of Akt/FOXO3a /GSK-3beta/AR signaling network by isoflavone in prostate cancer cells . J Biol Chem , 283 : 27707 – 27716 .
   PubMed Web of Science ®Google Scholar
• Lee , J , Ju , J , Park , S , Hong , S J and Yoon , S . 2012 . Inhibition of IGF-1 signaling by genistein: modulation of E-cadherin expression and downregulation of β-catenin signaling in hormone refractory PC-3 prostate cancer cells . Nutr Cancer , 64 : 153 – 162 .
   PubMed Web of Science ®Google Scholar
• Wang , Z , Zhang , Y , Banerjee , S , Li , Y and Sarkar , F H . 2006 . Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. International journal of cancer . Int J Cancer , 118 : 1930 – 1936 .
   PubMed Web of Science ®Google Scholar
• Jacobsen , B K , Knutsen , S F and Fraser , G E . 1998 . Does high soy milk intake reduce prostate cancer incidence? the adventist health study (United States) . Cancer Causes Control , 9 : 553 – 557 .
   PubMed Web of Science ®Google Scholar
• Hwang , Y W , Kim , S Y , Jee , S H , Kim , Y N and Nam , C M . 2009 . Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies . Nutr Cancer , 61 : 598 – 606 .
   PubMed Web of Science ®Google Scholar
• Yan , L and Spitznagel , E L . 2009 . Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis . Am J Clin Nutr , 89 : 1155 – 1163 .
   PubMed Web of Science ®Google Scholar
• Lazarevic , B , Boezelijn , G , Diep , L M , Kvernrod , K Ogren , O . 2011 . Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial . Nutr Cancer , 63 : 889 – 898 .
   PubMed Web of Science ®Google Scholar
• Kurahashi , N , Iwasaki , M , Sasazuki , S , Otani , T Inoue , M . 2007 . Soy product and isoflavone consumption in relation to prostate cancer in Japanese men . Cancer Epidemiol Biomarkers Prev , 16 : 538 – 545 .
   PubMed Web of Science ®Google Scholar
• Travis , R C , Allen , N E , Appleby , P N , Price , A Kaaks , R . 2012 . Prediagnostic concentrations of plasma genistein and prostate cancer risk in 1,605 men with prostate cancer and 1,697 matched control participants in EPIC . Cancer Causes Control , 23 : 1163 – 1171 .
   PubMed Web of Science ®Google Scholar
• Miyanaga , N , Akaza , H , Hinotsu , S , Fujioka , T Naito , S . 2012 . Prostate cancer chemoprevention study: An investigative randomized control study using purified isoflavones in men with rising prostate-specific . Cancer Sci , 103 : 125 – 130 .
   PubMed Web of Science ®Google Scholar
• Fischer , L , Mahoney , C , Jeffcoat , A R , Koch , M A Thomas , B E . 2004 . Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia . Nutr Cancer , 48 : 160 – 170 .
   PubMed Web of Science ®Google Scholar
• Kumar , N B , Krischer , J P , Allen , K , Riccardi , D Besterman-Dahan , K . 2007 . Safety of purified isoflavones in men with clinically localized prostate cancer . Nutr Cancer , 59 : 169 – 175 .
   PubMed Web of Science ®Google Scholar
• Guy , L , Védrine , N , Urpi-Sarda , M , Gil-Izquierdo , A Al-Maharik , N . 2008 . Orally administered isoflavones are present as glucuronides in the human prostate . Nutr Cancer , 60 : 461 – 468 .
   PubMed Web of Science ®Google Scholar
• Manach , C , Williamson , G , Morand , C , Scalbert , A and Rémésy , C . 2005 . Bioavailability and bioefficacy of polyphenols in humans.I.Review of 97 bioavailability studies . Am J Clin Nutr , 81 : 230S – 242S .
   PubMed Web of Science ®Google Scholar
• Jian , L , Xie , L P , Lee , A H and Binns , C W . 2004 . Protective effect of green tea against prostate cancer: a case-control study in southeast China . Int J Cancer , 108 : 130 – 135 .
   PubMed Web of Science ®Google Scholar
• Kurahashi , N , Sasazuki , S , Iwasaki , M , Inoue , M and Tsugane , S . 2008 . Green tea consumption and prostate cancer risk in Japanese men: a prospective study . Am J Epidemiol , 167 : 71 – 77 .
   PubMed Web of Science ®Google Scholar
• Mori , M , Masumori , N , Fukuta , F , Nagata , Y and Sonoda , T . 2009 . Traditional Japanese diet and prostate cancer . Mol Nutr Food Res , 53 : 191 – 200 .
   PubMed Web of Science ®Google Scholar
• Li , X , Li , J , Tsuji , I , Nakaya , N Nishino , Y . 2008 . Mass screening-based case-control study of diet and prostate cancer in Changchun, China . Asian J Androl , 10 : 551 – 560 .
   PubMed Web of Science ®Google Scholar
• Davalli , P , Rizzi , F , Caporali , A , Pellacani , D Davoli , S . 2012 . Anticancer activity of green tea polyphenols in prostate gland . Oxid Med Cell Longev , : 2012
   Google Scholar
• McLarty , J , Bigelow , R LH , Smith , M , Elmajian , D Ankem , M . 2009 . Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro . Cancer Prev Res (Phila) , 2 : 673 – 682 .
   PubMed Web of Science ®Google Scholar
• Adhami , V M , Malik , A , Zaman , N , Sarfaraz , S Siddiqui , IA . 2007 . Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo . Clin Cancer Res , 13 : 1611 – 1619 .
   PubMed Web of Science ®Google Scholar
• Bettuzzi , S , Brausi , M , Rizzi , F and Castagnetti , G . 2006 . Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study . Cancer Res , 66 : 1234 – 1240 .
   PubMed Web of Science ®Google Scholar
• Kikuchi , N , Ohmori , K , Shimazu , T , Nakaya , N Kuriyama , S . 2006 . No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study . Br J Cancer , 95 : 371 – 373 .
   PubMed Web of Science ®Google Scholar
• Ullmann , U , Haller , J , Decourt , J P , Girault , N Girault , J . 2003 . A single ascending dose study of epigallocatechin gallate in healthy volunteers . J Int Med Res , 31 : 88 – 101 .
   PubMed Web of Science ®Google Scholar
• Chow , H-HS , Cai , Y , Hakim , I A , Crowell , J A Shahi , F . 2003 . Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals . Clin Cancer Res , 9 : 3312 – 3319 .
   PubMed Web of Science ®Google Scholar
• Nguyen , M M , Ahmann , F R , Nagle , R B , Hsu , C-H Tangrea , J A . 2012 . Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities . Cancer Prev Res (Phila) , 5 : 290 – 298 .
   PubMed Web of Science ®Google Scholar
• Henning , S M , Aronson , W , Niu , Y , Conde , F Lee , N H . 2006 . Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption . J Nutr , 136 : 1839 – 1843 .
   PubMed Web of Science ®Google Scholar
• Zhou , H , Beevers , C S and Huang , S . 2011 . The targets of curcumin . Curr Drug Targets , 12 : 332 – 347 .
   PubMed Web of Science ®Google Scholar
• Dorai , T , Gehani , N and Katz , A . 2000 . Therapeutic potential of curcumin in human prostate cancer-I curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells . Prostate Cancer Prostatic Dis , 3 : 84 – 93 .
   PubMed Web of Science ®Google Scholar
• Ide , H , Tokiwa , S , Sakamaki , K , Nishio , K Isotani , S . 2010 . Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen . Prostate , 70 : 1127 – 1133 .
   PubMed Web of Science ®Google Scholar
• Lao , C D , Ruffin , M T , Normolle , D , Heath , D D Murray , S I . 2006 . Dose escalation of a curcuminoid formulation . BMC Complem Altern M , 6 : 10
   PubMedGoogle Scholar
• Cheng , A L , Hsu , C H , Lin , J K , Hsu , M M Ho , Y F . 2001 . Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions . Anticancer Res , 21 : 2895 – 2900 .
   PubMed Web of Science ®Google Scholar
• Sharma , R A , McLelland , H R , Hill , K A , Ireson , C R Euden , S A . 2001 . Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer . Clin Cancer Res , 7 : 1894 – 900 .
   PubMed Web of Science ®Google Scholar
• Sharma , R A , Euden , S A , Platton , S L , Cooke , D N Shafayat , A . 2004 . Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance . Clin Cancer Res , 10 : 6847 – 6854 .
   PubMed Web of Science ®Google Scholar
• Garcea , G , Berry , D P , Jones , D JL , Singh , R Dennison , A R . 2005 . Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences . Cancer Epidemiol Biomarkers Prev , 14 : 120 – 125 .
   PubMed Web of Science ®Google Scholar
• Anand , P , Kunnumakkara , A B , Newman , R A and Aggarwal , B B . 1995 . Bioavailability of curcumin: problems and promises . Mol Pharm , 4 : 807 – 818 .
   Web of Science ®Google Scholar
• Wahlang , B , Pawar , Y B and Bansal , A K . 2011 . Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model . Eur J Pharm Biopharm , 77 : 275 – 282 .
   PubMed Web of Science ®Google Scholar
• Maiti , K , Mukherjee , K , Gantait , A , Saha , B P and Mukherjee , P K . 2007 . Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats . Int J Pharm , 330 : 155 – 163 .
   PubMed Web of Science ®Google Scholar
• Kakkar , V , Singh , S , Singla , D and Kaur , I P . 2011 . Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin . Mol Nutr Food Res , 55 : 495 – 503 .
   PubMed Web of Science ®Google Scholar
• Bansal , S S , Goel , M , Aqil , F , Vadhanam , M V and Gupta , R C . 2011 . Advanced drug delivery systems of curcumin for cancer chemoprevention . Cancer Prev Res (Phila) , 4 : 1158 – 1171 .
   PubMed Web of Science ®Google Scholar
• Bisht , S , Feldmann , G , Soni , S , Ravi , R Karikar , C . 2007 . Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy . J Nanobiotechnology , 5 : 3
   PubMedGoogle Scholar
• Li , L , Braiteh , F S and Kurzrock , R . 2005 . Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis . Cancer , 104 : 1322 – 1133 .
   PubMed Web of Science ®Google Scholar
• Rayman , M P . 2012 . Selenium and human health . Lancet , 379 : 1256 – 1268 .
   PubMed Web of Science ®Google Scholar
• Duffield-Lillico , A J , Dalkin , B L , Reid , M E , Turnbull , B W Slate , E H . 2003 . Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial . BJU International , 91 : 608 – 612 .
   PubMed Web of Science ®Google Scholar
• Dunn , B K , Richmond , E S , Minasian , L M , Ryan , A M and Ford , L G . 2010 . A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) . Nutr Cancer , 62 : 896 – 918 .
   PubMed Web of Science ®Google Scholar
• Klein , E A , Thompson , I M , Tangen , C M , Crowley , J J Lucia , M S . 2011 . Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) . JAMA , 306 : 1549 – 1556 .
   PubMed Web of Science ®Google Scholar
• Dennert , G , Zwahlen , M , Brinkman , M , Vinceti , M Zeegers , M PA . 2011 . Selenium for preventing cancer Cochrane database of systematic reviews (Online) . CD005195
   Google Scholar
• Joniau , S , Goeman , L , Roskams , T , Lerut , E Oyen , R . 2007 . Effect of nutritional supplement challenge in patients with isolated high-grade prostatic intraepithelial neoplasia . Urology , 69 : 1102 – 1106 .
   PubMed Web of Science ®Google Scholar
• Marshall , J R , Tangen , C M and Sakr , W A . 2011 . Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia . Cancer Prev Res (Phila) , 4 : 1761 – 1769 .
   PubMed Web of Science ®Google Scholar
• Wright , M E , Weinstein , S J , Lawson , K A , Albanes , D Subar , A F . 2007 . Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study . Cancer Epidemiol Biomarkers Prev , 16 : 1128 – 1135 .
   PubMed Web of Science ®Google Scholar
• Wu , K , Erdman , J W , Schwartz , S J , Platz , E A Leitzmann , M . 2004 . Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study . Cancer Epidemiol Biomarkers Prev , 13 : 260 – 269 .
   PubMed Web of Science ®Google Scholar
• Neuhouser , M L , Barnett , M J , Kristal , A R , Ambrosone , C B King , I B . 2009 . Dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy Trial . Cancer Epidemiol Biomarkers Prev , 18 : 2202 – 2206 .
   PubMed Web of Science ®Google Scholar
• Bosetti , C , Talamini , R , Montella , M , Negri , E Conti , E . 2004 . Retinol, carotenoids and the risk of prostate cancer: a case-control study from Italy . Int J Cancer , 112 : 689 – 692 .
   PubMed Web of Science ®Google Scholar
• Peters , U , Leitzmann , M F , Chatterjee , N , Wang , Y Albanes , D . 2007 . Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial . Cancer Epidemiol Biomarkers Prev , 16 : 962 – 968 .
   PubMed Web of Science ®Google Scholar
• Karppi , J , Kurl , S , Laukkanen , J A and Kauhanen , J . 2012 . Serum β-carotene in relation to risk of prostate cancer: the Kuopio Ischaemic Heart Disease Risk Factor study . Nutr Cancer , 64 : 361 – 367 .
   PubMed Web of Science ®Google Scholar
• Huang , C-S , Fan , Y-E , Lin , C-Y and Hu , M-L . 2007 . Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1 . J Nutr Biochem , 18 : 449 – 456 .
   PubMed Web of Science ®Google Scholar
• Liu , X , Allen , J D , Arnold , J T and Blackman , M R . 2008 . Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells . Carcinogenesis , 29 : 816 – 823 .
   PubMed Web of Science ®Google Scholar
• Giovannucci , E , Rimm , E B , Liu , Y , Stampfer , M J and Willett , W C . 2002 . A prospective study of tomato products, lycopene, and prostate cancer risk . J Natl Cancer Inst , 94 : 391 – 398 .
   PubMed Web of Science ®Google Scholar
• van Breemen , R B , Sharifi , R , Viana , M , Pajkovic , N Zhu , D . 2012 . Antioxidant effects of lycopene in african american men with prostate cancer or benign prostate hyperplasia: a randomized controlled trial . Cancer , 4 : 711 – 718 .
   Web of Science ®Google Scholar
• Mohanty , N K , Saxena , S , Singh , U P , Goyal , N K and Arora , R P . 2005 . Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia . Urol Oncol , 23 : 383 – 385 .
   PubMed Web of Science ®Google Scholar
• Schwarz , S , Obermu , U C , Hellmis , E and Koch , W . 2008 . Lycopene inhibits disease progression in patients with benign prostate hyperplasia . Prostate , 138 : 49 – 53 .
   Google Scholar
• Bunker , C H , McDonald , A C , Evans , R W , de la Rosa , N Boumosleh , J M . 2007 . A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk . Nutr Cancer , 57 : 130 – 137 .
   PubMed Web of Science ®Google Scholar
• Kristal , A R , Till , C , Platz , E A , Song , X King , I B . 2011 . Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial . Cancer Epidemiol Biomarkers Prev , 20 : 638 – 646 .
   PubMed Web of Science ®Google Scholar
• Ilic , D and Misso , M . 2012 . Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: A systematic review . Maturitas , 72 : 269 – 276 .
   PubMed Web of Science ®Google Scholar